PKM2 in carcinogenesis and oncotherapy

This is the authors' abstract. We don't add key points for this paper.

// Xia He 1, * , Suya Du 2, * , Tiantian Lei 2, * , Xiang Li 2, * , Yilong Liu 3 , Hailian Wang 4 , Rongsheng Tong 1 and Yi Wang 1 1 Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China 2 School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China 3 Department of Pharmacy, The People’s Hospital of Leshan, Leshan, Sichuan 614000, China 4 Institute of Organ Transplantation, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China * These authors have contributed equally to this work Correspondence to: Yi Wang, email: w_yi@yahoo.com Rongsheng Tong, email: tongrs@126.com Keywords: PKM2; Warburg effect; aerobic glycolysis; carcinogenesis; oncotherapy Received: August 16, 2017 Accepted: October 28, 2017 Published: November 20, 2017 ABSTRACT Tumor cell metabolism is characterized by abundant glucose consumption and aerobic glycolysis. And pyruvate kinase M2 (PKM2) plays a decisive role in glycolysis, significantly contributing to the Warburg effect, tumor growth, angiogenesis, cell division, metastasis and apoptosis. To date, researchers have unraveled the potential of pyruvate kinase M2 as an antitumor target, which suggests a new orientation for oncotherapy. Herein, we focus on the role of pyruvate kinase M2 in tumor cell development and its function as a potential new therapeutic target for tumor treatment. Besides, research actuality on pyruvate kinase M2-dependent glycometabolism and signaling pathway in tumors is also summarized, providing valuable suggestions for further study in this field.